Skip to content
GLP-1 Decoder

Victoza for PCOS: Evidence, Eligibility, Coverage

Victoza is not FDA approved for polycystic ovary syndrome (PCOS). It is approved for type 2 diabetes and heart risk. Some doctors prescribe it when one of those uses also applies. In SCALE Obesity and Prediabetes, people on Saxenda lost 7.4% of body weight on average, vs 3% on placebo.

Active ingredient
liraglutide
How it is taken
daily injection
Approved for
Type 2 diabetes and heart risk
Best result (SCALE Obesity and Prediabetes)
7.4% weight loss

Victoza in brief

How long it stays in your body
100%50%25%0%013 h26 h39 h2.2 d2.7 d50%25%12.5%time after the dose

The half-life is about 13 hours: after 13 h, half is gone, and after five half-lives (2.7 d), about 3% remains.

Weight lost in the main trial
Victoza (LEAD-3)2.5 kgPlacebo1.1 kg

In LEAD-3, people with type 2 diabetes lost 2.5 kg over 52 weeks, compared with 1.1 kg on placebo.

Label source: FDA label (DailyMed).

Who qualifies?

Victoza: who qualifies
Who sets the ruleWho qualifies
FDA labelAlong with diet and exercise, this medicine lowers blood sugar in adults and children 10 and older with type 2 diabetes.
FDA labelThis medicine lowers the chance of heart attack, stroke, or heart-related death in adults with heart disease and type 2 diabetes.
Typical commercial plan (Aetna policy)BMI 30 or higher
Typical commercial plan (Aetna policy)BMI 27 or higher with a weight-related condition
Typical commercial plan (Aetna policy)a program of diet and activity for 6 months comes first

Sources: FDA label (DailyMed), aetna.com.

Trial results for PCOS

In every trial, enrollment was not limited to polycystic ovary syndrome (PCOS). The adults involved had obesity or overweight but did not have type 2 diabetes.

The same ingredient (liraglutide) was tested in these trials
TrialMedicineWho took partLengthPeopleMain resultComparison
SCALE Obesity and Prediabetes SaxendaAdults with obesity or overweight, without type 2 diabetes56 weeks3,7317.4% weight loss3% on placebo

Trial sources: SCALE Obesity and Prediabetes (FDA label (DailyMed)).

What is different for PCOS?

Label details: Victoza and polycystic ovary syndrome (PCOS)
What changesWhat the label says
HypoglycemiaUsing it with insulin or a sulfonylurea raises the risk of low blood sugar. The doses of those medicines may need lowering.

According to the FDA labels on DailyMed.

Label warning source: FDA label at DailyMed.

Coverage for PCOS

If a GLP-1 is used only for weight loss, Medicare Part D will not cover it.

When Medicaid covers weight-loss GLP-1s, prior authorization is the standard.

Sources: humana.com, KFF.

Alternatives for PCOS

Polycystic ovary syndrome (PCOS): GLP-1 medicines
MedicineFor PCOSHow it is takenTrial result
VictozaNot a listed usedaily injectionNot listed
OzempicNot a listed useweekly injectionNot listed
WegovyNot a listed useweekly injection or daily tablet14.9% weight loss
RybelsusNot a listed usedaily tabletNot listed
MounjaroNot a listed useweekly injectionNot listed
ZepboundNot a listed useweekly injection20.9% weight loss
FoundayoNot a listed usedaily tablet11.1% weight loss
TrulicityNot a listed useweekly injectionNot listed
SaxendaNot a listed usedaily injection7.4% weight loss
ByettaNot a listed usetwice-daily injectionNot listed

Label source: FDA label (DailyMed).

Ask your prescriber these questions

Read the full Victoza prescribing information on DailyMed.